Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | NPY1R | P25929 | 1/20 | 0.32 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29891154 | 1.00 | GAA (0.40) | GAAKDM4EHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL31537484 | 0.95 | GAA (0.40) | GAAKDM4EHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL31394282 | 0.89 | KDM4E (0.35) | GAAKDM4EHPGDALDH1A1EGFR | |
| SCHEMBL24745852 | 0.88 | ALDH1A1 (0.44) | KDM4EHPGDALDH1A1EGFRHTT | |
| SCHEMBL12470442 | 0.87 | PKM (0.34) | GAAKDM4EHPGDALDH1A1EGFR | |
| SCHEMBL23240469 | 0.85 | CA1 (0.40) | GAAKDM4EHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL16113392 | 0.85 | UCHL1 (0.33) | GAAKDM4EHPGDALDH1A1EGFR | |
| SCHEMBL24746071 | 0.84 | EGFR (0.33) | EGFRUCHL1CYP3A4 | |
| SCHEMBL25287007 | 0.84 | EGFR (0.41) | GAAKDM4EHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL22140531 | 0.84 | KDM4E (0.47) | GAAKDM4EHPGDALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4291235-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2023-12-20 | — | — | EP | disclosed |
| CN-117120090-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| EP-4211121-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | Genzyme Corporation (US) | 2023-07-19 | — | — | EP | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
| WO-2022056447-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2014026327-A1 | 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORGAMMAT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2014-02-20 | — | — | WO | disclosed |
| US-20140038942-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-02-06 | — | — | US | disclosed |
| US-20140038942-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-02-06 | — | — | US | disclosed |
| US-20140038942-A1 | RORgammaT INHIBITORS | MERCK SHARP & DOHME B.V. (NL) | 2014-02-06 | — | — | US | disclosed |
| EP-2683693-A1 | RORGAMMAT INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-01-15 | — | — | EP | disclosed |
| WO-2012106995-A1 | RORGAMMAT INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-08-16 | — | — | WO | disclosed |
| WO-2012106995-A1 | RORGAMMAT INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-08-16 | — | — | WO | disclosed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| EP-2155202-A2 | 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AND 3,5-DISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138889-A2 | 3, 6-DISUBSTITUTED-IMIDAZO [1, 2-B] PYRIDAZINES AND 3, 5-DISUBSTITUTED PYRAZOLO[1, 5-A] PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, PGM2 | GAA 9/4885KDM4E 3317/4885HPGD 255/4885 |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | GAA 905/4885KDM4E 3143/4885HPGD 413/4885 |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | GAA 2032/4885KDM4E 2784/4885HPGD 1182/4885 |
| US-20140038942-A1 | RORgammaT INHIBITORS | RORB, RORC, RORA | GAA 807/4885KDM4E 2919/4885HPGD 1928/4885 |
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINE1, SERPINA3 | GAA 133/4885KDM4E 4443/4885HPGD 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.